PULIKE(SH:603566)2021-10-28 16:00Financial Performance - The company's operating revenue for the third quarter reached ¥241,787,918.71, representing a year-on-year increase of 7.14%[6] - Net profit attributable to shareholders was ¥67,027,689.59, showing a significant increase of 65.72% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥50,565,525.04, up 117.87% year-on-year[6] - The basic earnings per share for the quarter was ¥0.21, with a year-to-date figure of ¥0.73, reflecting a 43.14% increase[6] - Total operating revenue for the first three quarters of 2021 reached ¥821,018,803.18, a 27% increase compared to ¥647,434,110.71 in the same period of 2020[34] - Net profit for the first three quarters of 2021 was ¥230,629,480.23, representing a 44% increase from ¥160,471,917.44 in the same period of 2020[38] - Earnings per share for the first three quarters of 2021 were ¥0.73, compared to ¥0.51 in the same period of 2020[40] Revenue Breakdown - The revenue from swine vaccines for the first nine months was ¥291,837,752.90, marking a 70.69% increase compared to the same period last year[11] - The revenue from poultry vaccines and antibodies was ¥280,321,630.33, which is a 7.71% increase year-on-year[11] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,120,119,014.46, a 4.50% increase from the end of the previous year[9] - The company's total liabilities were reported at CNY 853,364,267.26, compared to CNY 879,460,441.44 in the previous year[29] - The total liabilities as of the reporting date were ¥337,165,101.98, compared to ¥319,158,363.35 in the previous year[31] - Total equity attributable to shareholders reached ¥1,782,953,912.48, up from ¥1,709,645,282.25 in the previous year[31] Cash Flow - Operating cash inflows totaled $804,369,589.67, an increase from $664,903,082.43 in the previous period, reflecting a growth of approximately 21%[43] - Operating cash outflows amounted to $672,595,454.93, compared to $515,852,336.52 previously, indicating a rise of about 30%[43] - Net cash flow from operating activities was $131,774,134.74, down from $149,050,745.91, representing a decrease of around 12%[43] - Cash inflows from investment activities reached $677,652,291.92, a decline from $740,986,190.65, showing a decrease of approximately 8.5%[43] - The net cash flow from financing activities was negative at -$157,424,361.01, compared to -$191,840,359.27 previously[45] Shareholder Information - The company had a total of 15,339 common shareholders at the end of the reporting period[17] - The company repurchased 6,854,300 shares, representing 2.13% of the total share capital[24] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[24] Other Financial Metrics - The weighted average return on equity for the quarter was 3.83%, an increase of 1.32 percentage points compared to the previous year[9] - The company's cash and cash equivalents were reported at CNY 250,419,311.84, slightly down from CNY 253,653,282.38 at the end of 2020[25] - Accounts receivable increased to CNY 273,480,554.03 from CNY 205,117,342.36 year-over-year, indicating a growth of approximately 33.3%[25] - Inventory levels rose significantly to CNY 202,962,860.91, compared to CNY 133,808,728.77 at the end of 2020, reflecting a growth of about 51.7%[25] - The company reported a significant increase in other receivables, which rose to CNY 5,844,690.35 from CNY 2,715,520.64[25] - Deferred income tax liabilities increased to ¥11,510,983.19 from ¥11,226,528.01 year-over-year[31] - Research and development expenses for the first three quarters of 2021 were ¥60,255,011.11, down from ¥86,470,942.29 in 2020[34] - The company reported a net exchange gain of ¥4,609,056.67, compared to a loss of ¥587,107.28 in the previous year[34]